Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT)

Cancer Science

Volumn 103, Issue 11, 2012, Pages 1920-1928

  Liao, Zhong Li ^a   Tang, Xu Dong ^a   Lü, Mu Han ^a   Wu, Yu Yun ^a   Cao, Ya Ling ^a   Fang, Dian Chun ^a   Yang, Shi Ming ^a   Guo, Hong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIGEN; ANTINEOPLASTIC AGENT; CHROMIUM 51; EPITOPE; HLA A ANTIGEN; HLA A0201 ANTIGEN; MULTIPLE ANTIGEN PEPTIDE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL KILLING; CONTROLLED STUDY; DENDRITIC CELL; ENZYME ACTIVITY; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; VIRUS RECOMBINANT;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; GENETIC VECTORS; HEP G2 CELLS; HLA-A2 ANTIGEN; HUMANS; MICE; MICE, INBRED C57BL; NEOPLASMS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; TELOMERASE; VACCINES, SUBUNIT;

EID: 84868196835     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02410.x     Document Type: Article

References (47)

1. Stewart SA. Telomere maintenance and tumorigenesis. An "ALT" ernative road. Curr Mol Med 2005; 5: 253-7.
2. Janknecht R. On the road to immortality: hTERT upregulation in cancer cells. FEBS Lett 2004; 564: 9-13.
3. Nocellino L, Castelli C, Parmiani GA. Listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54: 187-207.
4. Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996; 66: 470-6.
5. Yee C, Thompson JA, Roche P et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med 2000; 192: 1637-42.
6. Schultze JL, Vonderheide RH. From cancer genomics to cancer immunotherapy: toward secondgeneration tumor antigens. Trends Immunol 2001; 22: 516-23.
7. Schultze JL, Maecker B, von Bergwelt-Baildon MS et al. Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens. Vox Sang 2001; 80: 81-9.
8. Vonderheide RH. Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie 2008; 90: 173-80.
9. Yu ST, Chen L, Wang HJ et al. hTERT Promotes the invasion of telomerase-negative tumor cells in vitro. Int J Oncol 2009; 35: 329-36.
10. Vonderheide RH, Domchek SM, Schultze JL et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004; 10: 828-39.
11. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 1993; 13: 2388-99.
12. Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993; 11: 213-44.
13. Chen L, Tang XD, Yu ST et al. Induction of anti-tumour immunity by dendritic cells transduced with hTERT recombinant adenovirus in mice. J Pathol 2009; 217: 685-92.
14. Chen L, Liang GP, Tang XD et al. In vitro anti-tumor immune response induced by dentritic cells transfected with hTERT recombinant adenovirus. Biochem Biophys Res Commun 2000; 351: 927-34.
15. Su Z, Dannull J, Yang BK et al. Telomerase mRNA-transfected dentritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastic prostate cancer. J Immunol 2005; 174: 3798-807.
16. Hernandez J, Schoeder K, Blondelle SE et al. Antigenicity and immunogenicity of peptide analogoues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigen. Eur J Immunol 2004; 34: 2331-41.
17. Minev B, Hipp J, Firat H, Shmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 2000; 97: 4796-801.
18. Dupont J, Latouche JB, Ma C, Sadelain M. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res 2005; 65: 5417-27.
19. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10: 673-9.
20. Huo LF, Tang JW, Huang JJ et al. Cancer immunotherapy targeting the telomerase reverse transcriptase. Cell Mol Immunol 2006; 3: 1-11.
21. Mocellin S, Pilati P, Nitti D. Peptide-based anticancer vaccines: recent advances and future perspectives. Curr Med Chem 2009; 16: 4779-96.
22. Lazoura E, Apostolopoulos V. Insights into peptide-based vaccine design for cancer immunotherapy. Curr Med Chem 2005; 12: 1481-94.
23. Pini A, Falciani C, Bracci L. Branched peptides as therapeutics. Curr Protein Pept Sci 2008; 9: 468-77.
24. Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density antigenic multiple antigenic peptide system. PNAS 1988; 85: 5409-13.
25. Chen T, Tang XD, Chen L et al. HLA-A0201-rstricted cytotoxic T lymphocyte epitopes from heparanase as novel targets for broad-spectrum tumor immunotherapy. Neoplasia 2008; 10: 977-86.
26. Tang X-D, Liang G-P, Li C et al. Cytotoxic T lymphocyte epitopes from human heparanase can elicit a potent anti-tumor immune response in mice. Cancer Immunol Immunother 2010; 59: 1041-7.
27. Bakker AB, Schreurs MW, de Boer AJ et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994; 179: 1005-9.
28. Iglesias MC, Mollier K, Beignon AS et al. Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. Mol Ther 2007; 15: 1203-10.
29. Marshall JL, Hoyer RJ, Toomey MA et al. Phase I study in advanced cancer patients of diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18: 3964-73.
30. Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY. Specific cytotoxic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res 2000; 6: 24-33.
31. Adotévi O, Mollier K, Neuveut C et al. Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Blood 2010; 115: 3025-32.
32. Sharma A, Tandon M, Bangari DS, Mittal SK. Adenoviral vector-based strategies for cancer therapy. Curr Drug Ther 2009; 4: 117-38.
33. Azuma I, Seya T. Development of immunoadjuvants for immunotherapy of cancer. Int Immunopharmacol 2001; 1: 1249-59.
34. Guo H, Hao J, Chao W, Shi Y, Zhao X-Y, Fang D-C. A novel peptide-nucleotide dual vaccine of human telomerase reverse transcriptase induces a potent cytotoxic T-cell response in vivo. Biochem Biophys Res Commun 2007; 357: 1090-5.
35. Wang G-Z, Tang X-D, Lü M-H et al. Multiple antigenic peptides of human heparanase elicit a much more potent immune response against tumors. Cancer Prev Res 2011; 4: 1285-95.
36. Defort JP, Nardelli B, Huang W, Tam JP. A rational design of synthetic peptide vaccine with a builtin adjuvant. A modular approach for unambiguity. Int J Pept Protein Res 1992; 40: 214-21.
37. Nardelli B, Tam JP. The MAP system: a flexible and unambiguous vaccine desigen of branched peptides. Pharm Biotechol 1995; 6: 803-19.
38. Tam JP. Recent advances in multiple antigen peptides. J Immunol Methods 1996; 196: 17-32.
39. Vogel T, Kurth R, Norley S. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. J Immunol 1994; 153: 1895-904.
40. Ciesielski MJ, Kazim AL, Barth RF, Fenstermaker RA. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol Immunother 2005; 54: 107-19.
41. Manki A, Ono T, Uenaka A, Seino Y, Nakayama E. Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia. Cancer Res 1998; 58: 1960-4.
42. Sadler K, Tam JP. Peptide dendrimers: applications and synthesis. Mol Biotechnol 2002; 90: 195-229.
43. Ota S, Ono T, Morita A, Uenaka A, Harada M, Nakayama E. Cellular processing of a multibranched lysine core with tumor antigen peptides and presentation of peptide epitopes recognized by cytotoxic t lymphocytes on antigen-presenting cells. Cancer Res 2002; 62: 1471-6.
44. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54: 721-8.
45. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421: 852-6.
46. Janssen EM, Droin NM, Lemmens EE et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005; 434: 88-93.
47. Danet-Desnoyers GA, Jennifer LL, Bonnet DA, Domcheka SM, Vonderheidea RH. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Exp Hematol 2005; 33: 1275-80.